Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes-Reference-Cited by-同舟云学术

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes

Published:2016-09 Issue: Volume:8 Page:1280-1288
ISSN:2352-3409
Container-title:Data in Brief
language:en
Short-container-title:Data in Brief

Author:

Wasiak Sylwia,Gilham Dean,Tsujikawa Laura M.,Halliday Christopher,Norek Karen,Patel Reena G.,McLure Kevin G.,Young Peter R.,Gordon Allan,Kulikowski Ewelina,Johansson Jan,Sweeney Michael,Wong Norman C.

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference80 articles.

1. RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease;Gilham;Atherosclerosis,2016

2. The acute phase response and atherosclerosis;Lowenstein;Drug Discov. Today,2004

3. Friend turns foe: transformation of anti-inflammatory HDL to proinflammatory HDL during acute-phase response;Bindu;Cholesterol,2011

4. Transcriptional fingerprint of human whole blood at the site of coronary occlusion in acute myocardial infarction;Muller;EuroIntervention,2011

5. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice;Bruemmer;J. Clin. Investig.,2003

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective BET inhibitor RVX‐208 ameliorates periodontal inflammation and bone loss;Journal of Clinical Periodontology;2023-10-19

2. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease;American Journal of Preventive Cardiology;2022-09

3. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study;Cardiovascular Diabetology;2021-01-07

4. Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease;Cardiovascular Therapeutics;2020-08-01

5. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes;JAMA;2020-04-28